GlaxoSmithKline (GSK) recently revealed that it had allied with Chinese Hengrui Pharma to co-develop up to 12 novel medicines. The collaboration was valued at potentially up to $12 billion and is intended to support GSK’s long-term growth
Akums Drugs & Pharmaceuticals Ltd., India’s largest contract manufacturing pharmaceutical company, is proud to announce that its Sterile Manufacturing Plant has received the prestigious Good Manufacturing Practice(GMP) Certificate from ANVISA...
In a major leap for India's biotech industry, accessible CAR-T therapy has not only reached patients sooner than expected but has also become commercially viable. ImmunoACT, the startup that created India's first indigenous CAR-T cell therapy...
The All India Organisation of Chemists and Druggists (AIOCD) is raising serious concerns about the unregulated modus operandi of illegal e-pharmacies in India. AIOCD sent a letter to the Drugs Controller General of India (DCGI) calling...
In a remarkable boost for innovation in antibiotics, Wockhardt's Zaynich has been mentioned in a top medical journal in the UK following a remarkable recovery case of a liver transplant patient with a pan-drug-resistant infection...
As part of a trend that is causing concern in the industry regarding the quality of drugs and adherence to across-the-board manufacturing standards, major Indian drugmakers such as Sun Pharma, Lupin and Dr Reddy Laboratories have initiated volunt...
Patent specialists are sounding the alarm about the intellectual property terms in the recently finalized India-UK Trade Pact, which they claim will restrict India's ability to ensure affordable access to essential medicines...
India's drug and pharmaceutical exports have increased by 92%, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, thanks to a number of initiatives the Center is implementing to realize the vision of Aatmanirbhar Bharat
The Delhi High Court has declined to issue directions to Zydus Lifesciences to disclose the manufacturing process of its breast cancer drug Sigrima, following a plea by Swiss multinational F. Hoffmann-La Roche.
Pfizer has entered a worldwide license deal, with the exception of China, with Chinese company 3SBio to obtain exclusive rights to develop, make, and sell 3SBio's investigational bispecific antibody, SSGJ-707.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")